Syndax Pharmaceuticals (SNDX) Other Non-Current Liabilities (2015 - 2025)
Syndax Pharmaceuticals' (SNDX) quarterly Other Non-Current Liabilities came in at $4.8 million in Q2 2025, up 165.28% quarter-over-quarter from $1.8 million in Q1 2025.
Syndax Pharmaceuticals (SNDX) Other Non-Current Liabilities (2015 - 2025) Analysis & Trends
Syndax Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $4.8 million for Q2 2025.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $4.8 million in Q2 2025; TTM through Jun 2025 was $4.8 million, a N/A change from a year earlier, with the FY2024 full-year figure at $307000.0, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $4.8 million in Q2 2025 per SNDX's latest filing, from $1.8 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $4.8 million in Q2 2025 and bottomed at $307000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Syndax Pharmaceuticals | 1.87 Bn | 1.52 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.78 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 307,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 3,000.00 |
| Mar 31, 2020 | 4,000.00 |
| Dec 31, 2019 | 5,000.00 |
| Sep 30, 2019 | 6,000.00 |
| Jun 30, 2019 | 7,000.00 |
| Mar 31, 2019 | 7,000.00 |
| Dec 31, 2018 | 136,000.00 |
| Sep 30, 2018 | 148,000.00 |
| Jun 30, 2018 | 311,000.00 |
| Mar 31, 2018 | 312,000.00 |
| Dec 31, 2017 | 310,000.00 |
| Sep 30, 2017 | 267,000.00 |
| Jun 30, 2017 | 214,000.00 |
| Mar 31, 2017 | 148,000.00 |
| Dec 31, 2016 | 288,000.00 |